The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...

It’s not the first time Johnson’s pursuit of immortality has made the news. The 47-year-old allegedly spends about $2 million ...

Sanofi’s Sarclisa (isatuximab) has been approved by the Medicines and Healthcare product Regulatory Agency (MHRA) as part of a combination treatment for newly diagnosed multiple myeloma (MM).

Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from ...

Smart Business Evolution in Manufacturing Awards honor innovative Northeast Ohio manufacturers. See who we recognized this ...

The poster titled “Preclinical and Translational Pharmacokinetics of GD2-SADA, a Self-Assembling and Disassembling (SADA) Bispecific Fusion Protein for Pretargeted Radioimmunotherapy (PRIT)” ...

Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: REGN) today announced ...

There are no F.D.A.-approved treatments to target aging, but many of the offerings at longevity clinics are authorized for other conditions and can be used off label ... cells from the liquid ...

Here, the authors provide and validate a method to prepare, label, and image proteins at mammalian cell plasma membranes for sub-nanometer structural analysis.

Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.

The mother of a seven-year-old with a life-threatening blood disorder says despite treatments being the same as cancer, they ...